Dupixent: Safety During Pregnancy, Breastfeeding, and More

What Is Dupixent?

Dupixent is the brand name for dupilumab, a prescription biologic given by subcutaneous injection. It is a fully human monoclonal antibody that attaches to the interleukin-4 receptor alpha subunit. This blocks signaling from two inflammatory proteins, interleukin-4 and interleukin-13, which are major drivers of type 2 inflammation.

Depending on a patient’s age and diagnosis, Dupixent may be prescribed for conditions such as moderate-to-severe atopic dermatitis, certain forms of asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and other approved inflammatory disorders. It treats ongoing inflammation; it is not an emergency rescue treatment for an acute asthma attack.

Because Dupixent is a large antibody protein rather than a conventional small-molecule drug, it behaves differently in pregnancy and breast milk. That distinction matters when estimating how much medication may reach a fetus or nursing infant.

Is Dupixent Safe During Pregnancy?

What the FDA prescribing information says

The current U.S. prescribing information states that available case reports and case series have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. That wording is encouraging, but it does not mean researchers have proven that the medication carries zero risk. It means the evidence collected so far has not revealed a consistent safety signal.

The label also describes an animal study in which pregnant monkeys received an antibody targeting the same receptor at doses up to 10 times the maximum recommended human dose. Researchers did not observe treatment-related embryo-fetal toxicity, malformations, or harmful effects on the offspring’s development through six months of age. Animal findings cannot guarantee human safety, but they provide useful supporting information.

What human pregnancy research shows

MotherToBaby reported that published case reports and case series included more than 50 pregnancies with first-trimester dupilumab exposure and did not show an increased rate of birth defects. Those reports also had not identified an increased miscarriage risk, although formal studies designed specifically to measure miscarriage were still limited.

Evidence has grown beyond individual case reports. A nationwide retrospective cohort study involving 19 Italian referral centers evaluated pregnancies in patients with moderate-to-severe atopic dermatitis. Twenty-nine patients had dupilumab exposure, primarily during early pregnancy, and investigators did not identify an increased risk of adverse pregnancy, congenital, neonatal, or postpartum outcomes.

A larger propensity-matched cohort study published in 2025 also found no elevated risk of maternal adverse pregnancy outcomes among dupilumab-treated patients with type 2 inflammatory diseases. As with all retrospective research, the results can be influenced by differences in disease severity, healthcare access, treatment selection, and medical monitoring. The study is reassuring, but it cannot prove that Dupixent prevents complications or that every pregnancy will have the same outcome.

Additional published case series have documented patients who continued dupilumab through part or all of pregnancy, sometimes continuing during lactation, without an obvious pattern of medication-related maternal or infant complications. These include reports involving four patients, a clinical series of 13 patients, and multiple individual cases. An international multicenter case series published in 2026 has added further real-world information on gestational exposure.

Why the trimester of exposure matters

Dupilumab is an immunoglobulin G4 antibody. Human IgG naturally crosses the placenta through an active transport system that becomes increasingly efficient as pregnancy progresses. Placental transfer is generally lower early in pregnancy and greatest during the third trimester. Therefore, a fetus may receive more dupilumab after later-pregnancy doses than after an early first-trimester exposure.

This does not automatically mean third-trimester treatment is unsafe. It means clinicians should consider the timing of exposure, the mother’s diagnosis, disease severity, alternative treatments, previous flare history, and the possible consequences of stopping therapy.

What about miscarriage and birth defects?

Every pregnancy begins with background risks that exist regardless of medication use. In clinically recognized pregnancies in the United States, the estimated background risk is approximately 2% to 4% for major birth defects and 15% to 20% for miscarriage. Current Dupixent data have not shown these risks to be higher than expected, but the total number of carefully followed exposures remains modest compared with older medications.

There is even less information about childhood learning, behavior, immune development, or health many years after prenatal exposure. A normal delivery and newborn examination are excellent news, but long-term follow-up research remains valuable.

Why Stopping Treatment Is Not Automatically the Safer Choice

Medication risk is only half of the equation. The other half is the health impact of untreated disease.

Severe atopic dermatitis may cause relentless itching, disrupted sleep, skin infections, bleeding, stress, and substantial loss of quality of life. A person who previously required systemic treatment may flare after stopping Dupixent, sometimes within weeks. Published reports include patients who discontinued treatment after learning they were pregnant, experienced a significant recurrence, and restarted therapy after discussing the situation with their clinicians.

For someone using Dupixent for asthma, maintaining control can be especially important. Poorly or moderately controlled asthma during pregnancy is associated with higher risks of maternal preeclampsia, premature delivery, low birth weight, and having an infant who is small for gestational age. Dupixent should not replace a rescue inhaler, and inhaled or oral corticosteroids should never be reduced abruptly without medical supervision.

The practical goal is not to use the fewest medications at any cost. It is to use the safest effective treatment plan that keeps both the pregnant patient and fetus healthy.

Can You Breastfeed While Taking Dupixent?

The official FDA label remains cautious. It states that there are insufficient data on dupilumab concentrations in human milk, effects on the breastfed child, or effects on milk production. It recommends weighing the developmental and health benefits of breastfeeding against the mother’s need for treatment and any possible effects of the medication or untreated disease.

Why infant exposure is expected to be low

Dupilumab has a molecular weight of approximately 147,000 daltons, making it an exceptionally large molecule. Only a small amount is expected to move into mature breast milk. Any protein that reaches the milk is also likely to be partially broken down in the infant’s digestive tract, with minimal absorption into the bloodstreamparticularly after the first several days of life.

One published case measured a breast-milk dupilumab concentration of 1.1 milligrams per liter three days after a dose. This was approximately 1.3% of the simultaneous concentration in the mother’s plasma. A single measurement cannot predict exposure for every parent and baby, but it supports the expectation that milk transfer is limited.

What has happened in reported breastfed infants?

LactMed summarizes several reports involving breastfeeding during dupilumab treatment. These include eight patients who breastfed for periods ranging from about one month to more than 16 months, as well as other individual cases and small multicenter experiences. No adverse effects attributed to dupilumab were reported, and available follow-up described normal growth or development.

These numbers are still small. Extra caution may be appropriate for a premature infant, a medically fragile newborn, or a baby in the first days after delivery, when the intestinal lining may permit more protein absorption. LactMed notes that waiting at least two weeks after delivery before resuming treatment may reduce early transfer, but this is not a universal rule. Delaying a dose could be inappropriate when the mother’s condition is severe or unstable.

The decision should consider the infant’s gestational age and health, whether feeding is exclusive or partial, the mother’s diagnosis, and what happened during previous treatment interruptions.

Dupixent, Fertility, Contraception, and Paternal Exposure

Female fertility

Human studies have not established whether Dupixent affects the ability to become pregnant. Animal studies did not indicate impaired fertility. The U.S. prescribing information does not specify a mandatory contraception period or a standard preconception washout interval. That does not make planning unnecessary; it means the timing should be individualized rather than based on a one-size-fits-all countdown.

Paternal use

Human evidence involving fathers is limited, but animal studies did not identify reduced fertility. A small report described two men who used dupilumab during conception and throughout their partners’ pregnancies without reported birth defects. In general, a father’s medication exposure is much less likely to reach a pregnancy than medication taken by the pregnant person.

Side Effects to Watch for During Pregnancy or Breastfeeding

Pregnancy does not appear to create a completely new Dupixent side-effect profile. However, symptoms should not be dismissed as “just pregnancy,” especially when they are severe or new.

• Injection-site reactions: Redness, swelling, soreness, bruising, or itching may occur around the injection area.
• Eye problems: Conjunctivitis, dry eyes, eyelid inflammation, eye itching, and keratitis have been reported, particularly in patients treated for atopic dermatitis.
• Allergic reactions: Hives, facial swelling, breathing difficulty, faintness, or widespread rash require urgent medical attention.
• Joint symptoms: New or worsening joint pain, difficulty walking, stiffness, or reduced mobility should be reported. Arthralgia and new-onset psoriatic arthritis have been described.
• New skin conditions: Facial redness, scaling, burning, psoriasis, and other inflammatory reactions have been reported after approval.
• Eosinophilic complications: Patients using Dupixent for asthma should seek care for worsening shortness of breath, chest pain, fever, numbness, or other unusual systemic symptoms.

The FDA also recommends treating known parasitic worm infections before beginning Dupixent. Patients whose infection does not respond to antiparasitic treatment may need to pause Dupixent until the infection resolves.

Vaccines During Dupixent Treatment and After Prenatal Exposure

The Dupixent label recommends completing age-appropriate vaccinations before treatment when possible and avoiding live vaccines during therapy. Information about giving live vaccines together with Dupixent remains limited. In one adult study, antibody responses to two non-live vaccines were similar in Dupixent and placebo groups, although that study did not evaluate every vaccine or pregnancy.

Live vaccines are generally avoided during pregnancy even without Dupixent. CDC guidance recommends specific non-live vaccines during pregnancy based on timing, medical history, and current public-health recommendations. Most vaccines also do not interfere with breastfeeding.

Parents should tell the baby’s pediatrician about prenatal dupilumab exposure, especially when treatment continued into the third trimester. The pediatrician can decide whether exposure affects the timing of any live infant vaccine. Parents should not independently delay routine immunizations because Dupixent-specific evidence is still developing.

Questions to Discuss With Your Healthcare Team

• How severe was my condition before Dupixent, and what happened during previous treatment gaps?
• What are the risks of uncontrolled eczema, asthma, or another inflammatory condition in my pregnancy?
• Are there effective alternatives with more pregnancy data?
• Would continuing the current dose provide more benefit than stopping or spacing injections?
• How late in pregnancy might treatment continue?
• Should the newborn’s pediatrician receive a record of third-trimester exposure?
• Does my baby’s prematurity or medical condition change the breastfeeding recommendation?
• Which vaccines should I receive, and which should I avoid while on treatment?
• Is a pregnancy exposure registry currently accepting participants?

The FDA labeling notes a pregnancy exposure registry for people exposed to Dupixent. Registry availability and enrollment status can change, so patients can ask their prescriber or MotherToBaby for current information. Registries are important because every documented pregnancy helps replace guesswork with better evidence.

Real-World Experiences: What Treatment Decisions May Look Like

The following examples are educational composites based on themes reported in published cases and clinical studies. They are not quotations from individual patients and should not be treated as personalized medical advice.

Experience 1: Continuing treatment after severe eczema finally improves

Consider someone whose atopic dermatitis previously covered large areas of the body, interrupted sleep every night, and repeatedly became infected. After starting Dupixent, the itching becomes manageable, the skin barrier heals, and daily life stops revolving around jars of moisturizer and emergency laundry cycles.

When pregnancy occurs, the first instinct may be to stop every nonessential medication. However, the dermatologist and obstetrician may conclude that Dupixent is not merely a convenience. It is preventing severe inflammation, sleep loss, skin infections, and the need for repeated systemic corticosteroid treatment. After reviewing the limited but reassuring pregnancy evidence, the patient may choose to continue injections with routine obstetric monitoring.

This is the central theme in many reported experiences: the decision is not “medication versus no risk.” It is “medication exposure versus the known burden of active disease.”

Experience 2: Stopping Dupixent and experiencing a rapid flare

Another patient may discontinue Dupixent immediately after a positive pregnancy test. Two or three weeks later, itching returns, sleep disappears, and previously clear skin becomes inflamed. Pregnancy is tiring enough without spending midnight negotiating with an ice pack and a tube of moisturizer.

The care team may first strengthen topical treatment, skin care, wet wraps, trigger avoidance, or other pregnancy-compatible options. If the disease remains severe, restarting Dupixent may become the more reasonable choice. Several published reports describe successful restarts after a pregnancy-related interruption, followed by improved disease control and healthy infant outcomes. These reports are reassuring, although they cannot guarantee the same result for everyone.

Experience 3: Balancing asthma control with fetal exposure

For a patient with severe asthma, the conversation may be more urgent. Before biologic treatment, the person may have needed emergency visits, frequent oral corticosteroids, or hospitalization. In that situation, poorly controlled breathing poses an immediate risk to both parent and fetus.

The pulmonologist may recommend continuing Dupixent alongside standard controller inhalers. The patient should still keep a rescue inhaler available and follow an asthma action plan because Dupixent does not treat a sudden attack. Lung symptoms, rescue-inhaler use, and exacerbations may be monitored more closely throughout pregnancy.

Experience 4: Breastfeeding a healthy full-term infant

A parent who used Dupixent during pregnancy may wish to breastfeed after delivering a healthy full-term baby. The care team may explain that dupilumab is a large protein, milk levels are expected to be low, and the infant’s digestive system should break down much of what is swallowed. The published breastfeeding reports have not identified adverse effects, but experience remains limited.

Some parents continue on schedule. Others, when disease control permits, discuss delaying the first postpartum dose to reduce exposure during the earliest newborn period. A parent nursing a premature or medically fragile infant may receive a more cautious recommendation. None of these approaches is automatically correct for every family.

Experience 5: Coordinating care instead of collecting conflicting opinions

One of the most frustrating real-world experiences is hearing different answers from different specialists. The dermatologist understands the skin disease. The obstetrician understands pregnancy. The pediatrician understands newborn vulnerability. Meanwhile, the patient is left holding the syringe and wondering who gets the deciding vote.

The most useful solution is coordinated decision-making. The prescribing specialist can document disease severity and previous treatment failures. The obstetrician can assess pregnancy-specific risks. The pediatrician can prepare for feeding and vaccination questions. The patient contributes the most important information of all: personal goals, acceptable uncertainty, previous flares, and how badly the condition affects daily life.

A shared plan also prevents abrupt medication changes, missed asthma therapy, delayed treatment for side effects, and unnecessary anxiety. In pregnancy, clarity is a treatment tool too.

The Bottom Line

Current evidence on Dupixent during pregnancy is increasingly reassuring. FDA labeling, pregnancy case reports, multicenter series, and observational cohort studies have not identified a consistent increase in major birth defects, miscarriage, or maternal pregnancy complications. Nevertheless, the evidence is still less complete than it is for older medications, and fetal exposure is expected to rise later in pregnancy as placental IgG transfer increases.

Breastfeeding exposure is expected to be low because dupilumab is a large protein and is poorly absorbed through an infant’s digestive tract. Limited milk measurements and reported breastfeeding experiences have not shown harmful infant effects, although extra caution may be appropriate for premature and newborn infants.

Dupixent should not be stopped automatically after pregnancy begins. For some patients, controlling severe eczema, asthma, or another inflammatory condition may offer greater overall benefit than avoiding medication exposure. The safest choice is the one developed through shared decision-making, informed by disease severity, pregnancy timing, alternative treatments, infant health, and the patient’s priorities.